Ascentage Pharma Group Inc.

This early-stage study is testing a new oral medication called HQP1351 for patients with chronic myeloid leukemia (CML) or a type of acute lymphoblastic leukemia (Ph+ ALL) that has stopped responding to or cannot tolerate standard treatments. The main goals are to find a safe and…

This large, late-stage trial is testing if adding a new drug called lisaftoclax to the standard treatment (azacitidine) helps people with newly diagnosed high-risk MDS live longer. About 490 participants worldwide will be randomly assigned to receive either the new combination or…

This study is testing the safety and dosing of a new oral drug called lisaftoclax, both by itself and combined with other cancer drugs, for people with acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The goal is to find the safest and most effe…

This study is testing whether a daily pill called APG-2575 can help control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to standard treatments. About 75 adults whose cancer has progressed after previous therapies…

This global study is testing whether adding a new drug called lisaftoclax to a standard cancer therapy (BTK inhibitor) works better for controlling chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in patients who have already been on that standard therapy. About …

This large, late-stage trial is testing whether adding a new oral drug called APG-2575 (lisaftoclax) to a standard treatment (azacitidine) helps older adults with newly diagnosed acute myeloid leukemia (AML) live longer. The study will enroll about 486 patients worldwide who are …

This early-stage study is testing a new drug called APG-2575 for people with mild-to-moderate lupus. The main goals are to check if the drug is safe, see how the body processes it, and get a first look at whether it might help control lupus disease activity. About 40 participants…

This is the first human study testing a new experimental drug called APG-5918 for treating anemia. Researchers will give the drug to 105 healthy volunteers and people with chronic anemia to check if it's safe and how the body processes it. The study will also look for early signs…

This study is testing two experimental drugs, APG-115 and APG-2575, either alone or together, for adults with T-cell prolymphocytic leukemia (T-PLL) or non-Hodgkin's lymphoma (NHL) that has come back or hasn't responded to prior treatment. The main goals are to find safe doses an…

This study aims to understand how liver problems affect how the body processes the cancer drug olverembatinib. Researchers will compare 48 people with varying degrees of liver impairment to healthy volunteers after a single dose. The goal is to gather data to help doctors safely …